On February 18, 2018, OWC Pharmaceutical Research Corp appointed Dr. Oron Yacoby Zeevi as its Chief Scientific Officer (CSO) and Dr. Yehuda Baruch, who was OWC’s CSO, will now serve as Chief Medical and Regulatory Officer.
Brief Intro via 8K Filing:
Dr. Oron Yacoby Zeevi, age 57, Chief Scientific Officer : Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. In 2008, Dr. Yacoby Zeevi joined Neuroderm Ltd (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders as the Vice President of Research and was promoted to the position of VP R&D. From October 2016 until her recent departure, she served as Chief Scientific Officer of Neuroderm, which was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017. Dr. Yacoby Zeevi, is the inventor of over 50 issued patents and patents pending, Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D PoC, IP, CMC, early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs, towards development of commercially viable pharmaceutical or agricultural products. Dr. Yacobi Zeevi earned her PHD in micro biology and immunology from the Ben Gurion University of Be’er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem
Then, we’ll scroll down to the PR section of the 8K to see some quotes:
Dr. Yehuda Baruch, who will now assume the role of Chief Medical and Regulatory Officer of the OWC Pharmaceutical Research Corp. commented: “I am very pleased that we have reached a stage in our development where we were able to recruit a scientist of the caliber and background of Dr. Yacoby Zeevi. Her past scientific experience and achievements will greatly benefit our endeavors”.
Dr. Yacoby Zeevi stated “I am very proud to join OWCP and cooperate with their excellent management team in order to advance the Company to the next level. The Company has achieved a great deal in its clinical development to date and I am sure I can help in accelerating its growth.”
Mr. Mordechai Bignitz, Chief Executive Officer, commented on the appointment, “I am proud and honored to have Dr. Zeevi agree to join OWCP and assume the role of CSO. She brings with her immense pharmaceutical discovery and development knowledge, a unique set of skills and an exceptional track record, which contributed significantly to the success of her previous company. Her addition will complement our management team extremely well”.
So, there you have it. To someone who has been holding OWCP stock for the better part of a year in the red — this news makes you mad, doesn’t it? It’s the “the news” that’ll send OWCP back towards $3 any time soon. But, to the shareholders who have said consistently since 2017 that they’re holding into 2019 – 2020… This is reassurance. At least in my opinion.
If you want to do more due diligence on the new CSO, here is a profile of her on JewishWebsite and a story by ‘GLOBES’ (Israel’s Business Arena) titled, “How we achieved Israel’s biggest-ever pharma exit“. Then, finally, the official link to today’s PR from PRnewswire.com.